Abstract:Background and objective Caused by shared genetic risk factors and similar neuropsychological symptoms, bipolar disorder (BD) and major depressive disorder (MDD) are at high risk of misdiagnosis, which is associated with ineffective treatment and worsening of outcomes. We aimed to develop a machine learning (ML)-based diagnostic system, based on electronic medical records (EMR) data, to mimic the clinical reasoning of human physicians to differentiate MDD and BD (especially BD depressive episodes) patients about to be admitted to a hospital and, hence, reduce the misdiagnosis of BD as MDD on admission. In addition, we examined to what extent our ML model could be made interpretable by quantifying and visualizing the features that drive the predictions. Methods By identifying 16311 patients admitted to a hospital located in western China between 2009 and 2018 with a recorded main diagnosis of MDD or BD, we established three sub-cohorts with different combinations of features for both the MDD-BD cohort and the MDD-BD depressive episodes cohort, respectively. Four different ML algorithms (logistic regression, extreme gradient boosting (XGBoost), random forest, and support vector machine) and four train-test splits were used to train and validate diagnostic models, and explainable methods (SHAP and Break Down) were utilized to analyze the contribution of each of the features at both population-level and individual-level, including feature importance, feature interaction, and feature effect on prediction decision for a specific subject. Results The XGBoost algorithm provided the best test performance (AUC: 0.838 (0.810-0.867), PPV: 0.810 and NPV: 0.834) for separating patients with BD from those with MDD. Core predictors included symptoms (mood-up, exciting, bad sleep, loss of interest, talking, mood-down, provoke), along with age, job, myocardial enzyme markers (creatine kinase, hydroxybutyrate dehydrogenase), diabetes-associated marker (glucose), bone function marker (alkaline phosphatase), non-enzymatic antioxidant (uric acid), markers of immune/inflammation (white blood cell count, lymphocyte count, basophil percentage, monocyte count), cardiovascular function marker (low density lipoprotein), renal marker (total protein), liver biochemistry marker (indirect bilirubin), and vital signs like pulse. For separating patients with BD depressive episodes from those with MDD, the test AUC was 0.777 (0.732-0.822), with PPV 0.576 and NPV 0.899. Additional validation in models built with self-reported symptoms removed from the feature set, showed test AUC of 0.701 (0.666-0.736) for differentiating BD and MDD, and AUC of 0.564 (0.515-0.614) for detecting patients in BD depressive episodes from MDD patients. Validation in the datasets without removing the patients with comorbidity showed an AUC of 0.826 (0.806-0.846). Conclusion The diagnostic system accurately identified patients with BD in various clinical scenarios, and differences in patterns of peripheral markers between BD and MDD could enrich our understanding of potential underlying pathophysiological mechanisms of them.

Identifying influencing factors of metabolic syndrome in patients with major depressive disorder: A real-world study with Bayesian network modeling

Risk Factors for Anxiety in Major Depressive Disorder Patients

Development, Validation and Application of the Oxidative Stress Injury Biomarkers Model (BIOS Model) for Predicting Bipolar Disorder

Twenty-Five Cohorts of Major Depressive Disorder in China: Evidence for Reduced But Not Enhanced Default Mode Network Functional Connectivity

Prevalence and factors associated with metabolic syndrome in first hospitalization for major depression disorder patients

Association between thyroid dysfunction, metabolic disturbances, and clinical symptoms in first-episode, untreated Chinese patients with major depressive disorder: Undirected and Bayesian network analyses

Metabolic syndrome and depression: evidence from a cross-sectional study of real-world data in Japan

Evaluation of metabolomics-based urinary biomarker models for recognizing major depression disorder and bipolar disorder

Assessing the associations of 1,400 blood metabolites with major depressive disorder: a Mendelian randomization study

Metabolic indexes of obesity in patients with common mental disorders in stable stage

Bayesian network analysis of factors influencing type 2 diabetes, coronary heart disease, and their comorbidities

Employing biochemical biomarkers for building decision tree models to predict bipolar disorder from major depressive disorder

A study on the identification of factors related to depression in a population with an increasing number of chronic diseases in the short term in China based on a health ecology model

Explainable machine-learning algorithms to differentiate bipolar disorder from major depressive disorder using self-reported symptoms, vital signs, and blood-based markers

How mental health nursing can best improve service users' experiences and outcomes in inpatient settings: responses to a national consultation.

Investigating the network structure and causal relationships among bridge symptoms of comorbid depression and anxiety: A Bayesian network analysis

Detection study of bipolar depression through the application of model-based algorithm in terms of clinical feature and peripheral biomarkers

Identifying the Mediating Role of Socioeconomic Status on the Relationship Between Schizophrenia and Major Depressive Disorder: a Mendelian Randomisation Analysis

A Machine Learning Analysis of Big Metabolomics Data for Classifying Depression: Model Development and Validation

Genetic evidence for the causal relations between metabolic syndrome and psychiatric disorders: a Mendelian randomization study

The association between Metabolic Score for Visceral Fat and depression in overweight or obese individuals: evidence from NHANES